Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

UroGen Pharma (URGN) Gross Margin: 2017-2025

Historic Gross Margin for UroGen Pharma (URGN) over the last 7 years, with Sep 2025 value amounting to 88.07%.

  • UroGen Pharma's Gross Margin fell 220.00% to 88.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 87.95%, marking a year-over-year decrease of 232.00%. This contributed to the annual value of 90.18% for FY2024, which is 149.00% up from last year.
  • Latest data reveals that UroGen Pharma reported Gross Margin of 88.07% as of Q3 2025, which was up 3.20% from 85.34% recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Gross Margin registered a high of 90.80% during Q1 2024, and its lowest value of 85.34% during Q2 2025.
  • For the 3-year period, UroGen Pharma's Gross Margin averaged around 88.81%, with its median value being 88.65% (2023).
  • In the last 5 years, UroGen Pharma's Gross Margin skyrocketed by 397bps in 2024 and then crashed by 446bps in 2025.
  • UroGen Pharma's Gross Margin (Quarterly) stood at 90.18% in 2021, then crashed by 268bps to 87.49% in 2022, then soared by 279bps to 90.28% in 2023, then slumped by 34bps to 89.94% in 2024, then plummeted by 220bps to 88.07% in 2025.
  • Its last three reported values are 88.07% in Q3 2025, 85.34% for Q2 2025, and 88.50% during Q1 2025.